Northland Capital partners view: Today’s announcement brings Motif a step closer to US capital markets, where peers are valued at a significant premium to Motif. We believe that a NASDAQ
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, told DirectorsTalk today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to
Motif Bio Plc (LON:MTFB) CEO Graham Lumsden today noted an article entitled “Global Pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance”:
Motif Bio Plc (LON:MFTB) – It is hard to exaggerate the crisis looming in antibiotics. The World Health Organisation has warned of a potentially apocalyptic nightmare just around the corner,
The center for infectious disease research and policy last week published an article which states that the newly identified MCR-1 resistance gene has been detected in 6 more countries and
Politics will exert considerable influence on markets in 2016 with November’s US presidential election, the UK in/out referendum expected over the summer and the escalating tensions in the Middle East.
The Times: “There were fewer floats but the ones that got away did very well” (28.12.15) In a world still wary after the financial crisis, nerves about the potential to
Motif Bio’s Dr Graham Lumsden discusses the manufacturing of the Iclaprim clinical trial supplies in this exclusive interview with DirectorsTalk
Motif Bio Plc (LON:MTFB) CEO Dr Graham Lumsden spoke with DirectorsTalk to discuss the importance of this new milestone, why material was reprocessed and is there enough material for 2
Northland Capital’s Vadim Alexandre discusses the Motif Bio Plc Iclaprim Phase III announcement in this exclusive interview with DirectorsTalk
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
